Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?
Compared to the overall stock market, Eli Lilly (LLY -2.39%) has delivered some fairly ho-hum year-to-date returns, rising just 7% since January. Yet there’s a reason why it remains one of the most widely followed pharmaceutical stocks.
Eli Lilly continues to benefit greatly from the launch of its GLP-1 weight loss drugs. And on the horizon, a crop of new catalysts related to the stock’s existing catalyst could get it firing on all cylinders once again.
Image source: Getty Images.
Eli Lilly and its next big catalyst
During Q1 2026, overall sales increased by 56% year over year, thanks largely to increased sales of tirzepatide, Lilly’s “dual-agonist” GIP/GLP-1 treatment, sold under the Mounjaro name as a diabetes treatment, and as Zepbound as a weight loss treatment. Mounjaro sales increased 125%, while Zepbound sales were up 80%.
Today’s Change
(-2.39%) $-27.48
Current Price
$1,121.36
Key Data Points
Market Cap
Day’s Range
$1109.15 – $1161.94
52wk Range
$623.78 – $1249.45
Volume
10.6K
Avg Vol
3M
Gross Margin
82.83%
Dividend Yield
0.58%
However, investors have already priced in tirzepatide’s runaway success. Eli Lilly has been at work on retatrutide, a “triple G” agonist. According to phase 3 clinical trial data unveiled last month, the candidate “delivered substantial weight loss” among trial participants with obesity and related conditions, including type 2 diabetes and cardiovascular disease.
How soon could retatrutide drive the next rally?
Following the clinical trial, Eli Lilly plans to submit a Biologics License Application (BLA) with the Food and Drug Administration (FDA) early next year, suggesting a major project launch for 2027. This catalyst could soon have a greater impact on price action. Yes, investors more or less “sold the news” of the clinical trial data, as seen from the stock’s recent pullback.
Eli Lilly’s upcoming earnings release on Aug. 5 could spark further selling, especially as the stock remains far pricier than its peers at 34 times earnings. For better or worse, Q2 results will also provide a clearer picture of another Eli Lilly catalyst, the company’s recently launched Foundayo pill-based weight loss drug.
Unless these results — or guidance — suggest otherwise, growth remains on track. Long-term Eli Lilly investors may want to hold rather than take profits, while prospective buyers could benefit if further profit-taking creates a better entry point.
